Farràs Solé Núria, Wydh Sander, Alizadeh Bahmani Amir Hossein, Bui Thi Phuong Nam, Nieuwdorp Max
Department of Experimental Vascular Medicine, Amsterdam UMC, 1105 AZ Amsterdam, The Netherlands.
Department of Internal and Vascular Medicine, Amsterdam UMC, 1105 AZ Amsterdam, The Netherlands.
Int J Mol Sci. 2025 Sep 4;26(17):8609. doi: 10.3390/ijms26178609.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent liver disorder driven by metabolic dysregulation and inflammation. Recent studies highlight the importance of the gut microbiome as a key contributor to this pathology through its ability to ferment dietary sugars into ethanol, a metabolite previously overlooked in MASLD. In this review, we discuss the role of the gut microbiome in MASLD, covering functional and compositional shifts observed in the disease; we dive into the different microbial pathways of ethanol synthesis, hepatic mechanisms of ethanol clearance, and pathological consequences. We also discuss the role of a healthy microbiome in the clearance of ethanol in the gut and how microbiome-based strategies could be beneficial in targeting endogenous production of ethanol, going from the traditional probiotic-prebiotic combination to discussing new approaches.
代谢功能障碍相关脂肪性肝病（MASLD）是一种由代谢失调和炎症驱动的日益普遍的肝脏疾病。最近的研究强调了肠道微生物群作为这种病理状态关键促成因素的重要性，因为它能够将膳食糖发酵成乙醇，这是一种以前在MASLD中被忽视的代谢物。在这篇综述中，我们讨论了肠道微生物群在MASLD中的作用，涵盖了在该疾病中观察到的功能和组成变化；我们深入探讨了乙醇合成的不同微生物途径、乙醇清除的肝脏机制以及病理后果。我们还讨论了健康微生物群在肠道中清除乙醇的作用，以及基于微生物群的策略如何可能有利于针对内源性乙醇产生，从传统的益生菌 - 益生元组合到讨论新方法。
